menu
    • menu
    [{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Acquisition","leadProduct":"ORM-6151","moa":"CD33\/GSPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Bristol Myers Squibb","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"ORM-6151","moa":"CD33\/GSPT1","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Orum Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Orum Therapeutics","sponsor":"Imm Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2021","type":"Series B Financing","leadProduct":"ORM-5029","moa":"E3 ubiquitin ligase pathway","graph1":"Oncology","graph2":"Phase I","graph3":"Orum Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Orum Therapeutics \/ Imm Investment","highestDevelopmentStatusID":"6","companyTruncated":"Orum Therapeutics \/ Imm Investment"}]

    Find Clinical Drug Pipeline Developments & Deals by Orum Therapeutics

    Menu

    Orum Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orum Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-6151

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $280.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Orum Therapeutics Announces Acquisition of ORM-6151 Program by Bristol Myers Squibb

                            Details : BMS has acquired Orum’s ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader that has received the FDA’s clearance for Phase 1 for the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndromes.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $100.0 million

                            November 06, 2023

                            Lead Product(s) : ORM-6151

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Bristol Myers Squibb

                            Deal Size : $280.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-6151

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision ...

                            Details : ORM-6151 is the second drug candidate from Orum’s Dual-Precision Targeted Protein Degradation (TPD2 TM) approach, which combines the catalytic mechanism of TPDs with the precision of tumor-targeting therapeutic antibodies.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 10, 2022

                            Lead Product(s) : ORM-6151

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orum Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of ORM-5029 in Development to Treat ...

                            Details : ORM-5029 is a first-in-class drug candidate designed to selectively deliver catalytic GSPT1 protein degraders to HER2-expressing tumor cells via antibody targeting. The study is designed to evaluate the safety, pharmacokinetics, and preliminary anti-tumo...

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 31, 2022

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

                            Details : ORM-5029 is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            August 23, 2022

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orum Therapeutics Presents Preclinical Data at AACR 2022 Highlighting Novel Dual-Precision Targeted Protein De...

                            Details : ORM-5029, a potential first-in-class TPD therapy for HER2-positive cancer, displays robust efficacy both in vitro and in vivo compared to other small molecule GSPT1 degraders and approved antibody drug conjugates (ADCs).

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            April 08, 2022

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Orum Therapeutics to Present Preclinical Data for ORM-5029, a Novel Antibody Neodegrader Conjugate, at the AAC...

                            Details : ORM-5029, a potential first-in-class targeted protein degrader therapy is built on novel targeted protein degrader combined with the precise tumor cell delivery mechanisms of antibodies for HER2-expressing breast cancer.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            March 08, 2022

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            Orum Therapeutics

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Imm Investment

                            Deal Size : $84.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Orum Therapeutics Closes $84 Million Series B Financing to Advance Novel Targeted Protein Degrader Payloads in...

                            Details : The lead therapeutic programs from Orum’s AnDC platform are ORM-5029 for the treatment of solid tumors and ORM-6151 for the treatment of hematological cancers.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            June 24, 2021

                            Lead Product(s) : ORM-5029

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Imm Investment

                            Deal Size : $84.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth